Diflucan prophylaxis of fungal infections in bone marrow transplantation.

Diflucan effectiveness was assessed in 42 recipients of bone marrow. It was given in a dose 200 mg/day from the first conditioning day and was raised to 400 mg/day in administration of antibiotics. A prophylactic dose 200 mg was used in 4 patients, 400 mg-in 23(55%), 600 mg-in 4 patients who developed esophagitis. Diflucan was changed for amphotericin B in 11 (26%) patients because of fever in antibiotic treatment (9 cases), esophagitis (2 cases). Median of overall duration of diflucan use for prophylaxis of fungal infection was 28 days (from 18 to 43 days), In diflucan treatment contamination with Candida in the posttransplantation period was not recorded in 14 out of 42(33%) patients. Mucosal Candida involvement occur-red in 3(7%) recipients of the bone marrow, surface candidiasis was diagnosed in 14(33%) patients. Invasive candidiasis developed in one patient. Tolerance of Diflucan was good. In the course of myelotoxic agranulocytosis none of the patients died. Lethality within 100 days after bone marrow transplantation made up 4%.